Compared with the CERT1 originally developed by Zora Biosciences and validated in multiple prospective clinical studies [64], the sphingolipid-inclusive (SIC) risk score registered superiority in predicting CAD. The gene discussed is CERT1; the disease is coronary artery disorder.